|
Aug 8
|
European Equities Traded in the US as American Depositary Receipts Rise Friday
|
|
Aug 8
|
FDA removes Ixchiq partial pause but tightens vaccine’s use
|
|
Aug 7
|
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
|
|
Aug 5
|
VALNEVA Declaration of shares and voting rights: July 31, 2025
|
|
Jul 24
|
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?
|
|
May 13
|
High Growth Tech Stocks In Europe With Promising Potential
|
|
May 12
|
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns
|
|
May 12
|
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
|
|
Mar 3
|
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
|
|
Feb 28
|
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
|
|
Jan 3
|
VALNEVA Declaration of shares and voting rights: December 31, 2024
|
|
Oct 11
|
High Growth Tech Stocks In France October 2024
|
|
Oct 10
|
Valneva Hosts Investor Day in New York City
|
|
Oct 9
|
Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges
|
|
Oct 9
|
Exclusive Networks And 2 High Growth Tech Stocks In France
|
|
Oct 8
|
Exploring Three High Growth Tech Stocks in France
|
|
Aug 6
|
VALNEVA - Declaration of shares and voting rights: July 31, 2024
|
|
Jul 26
|
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
|
|
Jun 24
|
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
|
|
May 31
|
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
|